Cancer is one of the most devastating of all diseases. It takes thousands of lives each year and costs millions of dollars to treat. One of the most exciting companies to attack this problem is Seattle Genetics, located in Seattle, Washington.
This company was co-founded in 1998 by Dr. Clay Siegall. He is currently President, Chairman of the Board and CEO. Using the latest biotechnology, their aim is to use a direct treatment method, which will kill only the cancer cells while protecting the non-cancer ones. This technique is designed to reduce the deadly results of traditional chemotherapy.
Anti-body conjugates are their main product and include Adcetris, which is used for various types of lymphoma. These anti-body conjugates were developed jointly with Takeda Pharmaceutical Company Limited.
Dr. Siegall is well known in the medical field for his work in cancer research. After receiving a Ph.D in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland he became interested in improving current cancer treatment methods. Previous to founding Seattle Genetics, he worked for PDL Biopharma, MedImmune, the National Cancer Institute, Genentech, Curagen Corporation, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health.
Dr. Clay Siegall’s dedication to improving cancer treatment has been recognized with numerous awards such as University of Maryland Alumni of the Year and Pacific Northwest Ernst & Young Entrepreneur of the Year. He is a well-known author with over 70 publications, holds a number of patents and currently is a member of the Board of Directors of Alder BioPharmaceuticals.